Boston Scientific Corp (NYSE: BSX) kicked off on Friday, down -0.34% from the previous trading day, before settling in for the closing price of $90.42. Over the past 52 weeks, BSX has traded in a range of $54.95-$91.93.
Here's Your FREE Report on the #1 Small-Cap Uranium Stock of '24.
Small-cap Uranium stocks are booming in 2024! The company we're about to show you is the ONLY small-cap stock in the space that benefits from ALL aspects of the global Uranium industry with none of the risks of running a mine. Smart investors will not be hesitating on this one!
Get the FREE Report with all the details here.
Sponsored
Annual sales at Healthcare sector company grew by 8.10% over the past five years. While this was happening, its average annual earnings per share was recorded 20.05%. With a float of $1.47 billion, this company’s outstanding shares have now reached $1.47 billion.
Let’s look at the performance matrix of the company that is accounted for 48000 employees. In terms of profitability, gross margin is 67.3%, operating margin of 17.33%, and the pretax margin is 13.84%.
Boston Scientific Corp (BSX) Insider and Institutional Ownership
Our next focus will be how large-scale investors are participating in this stock of the Medical Devices Industry. The insider ownership of Boston Scientific Corp is 0.42%, while institutional ownership is 91.35%. The most recent insider transaction that took place on Dec 02 ’24, was worth 633,917. In this transaction EVP, Human Resources of this company sold 6,983 shares at a rate of $90.78, taking the stock ownership to the 29,308 shares. Before that another transaction happened on Nov 27 ’24, when Company’s SVP, Global Controller and CAO sold 1,336 for $90.65, making the entire transaction worth $121,105. This insider now owns 2,957 shares in total.
Boston Scientific Corp (BSX) Latest Financial update
According to the Wall Street analysts, stocks earnings will be around 20.05% per share during the next fiscal year. For the long-term projections, market analysts anticipate that the company’s EPS will surge by 14.20% during the next five years compared to -2.05% drop over the previous five years of trading.
Boston Scientific Corp (NYSE: BSX) Trading Performance Indicators
Take a look at Boston Scientific Corp’s (BSX) current performance indicators. Last quarter, stock had a quick ratio of 1.02. In addition, a publicly-traded company’s price to sales ratio for the trailing twelve months stands at 8.32. Likewise, its price to free cash flow for the trailing twelve months is 61.39.
For the trailing twelve months, Company’s Diluted EPS (Earnings per Share) is 1.21, a number that is poised to hit 0.66 in the next quarter and is forecasted to reach 2.80 in one year’s time.
Technical Analysis of Boston Scientific Corp (BSX)
Boston Scientific Corp (NYSE: BSX) saw its 5-day average volume 3.98 million, a negative change from its year-to-date volume of 5.97 million. As of the previous 9 days, the stock’s Stochastic %D was 65.02%. Additionally, its Average True Range was 1.47.
During the past 100 days, Boston Scientific Corp’s (BSX) raw stochastic average was set at 90.92%, which indicates a significant increase from 63.16% during the past two weeks. Based on volatility metrics of the stock, it showed a historical volatility of 12.10% in the past 14 days, which was lower than the 17.28% volatility it showed in the past 100 days.
At the time of writing, stock’s 50-day Moving Average is $87.86, while its 200-day Moving Average is $78.25. Nevertheless, the first resistance level for the watch stands at $90.74 in the near term. At $91.38, the stock is likely to face the second major resistance level. The third major resistance level sits at $91.72. If the price goes on to break the first support level at $89.76, it is likely to go to the next support level at $89.42. The third support level lies at $88.78 if the price breaches the second support level.
Boston Scientific Corp (NYSE: BSX) Key Stats
The company with the Market Capitalisation of 132.35 billion has total of 1,473,827K Shares Outstanding. Its annual sales at the moment are 14,240 M in contrast with the sum of 1,591 M annual income. Company’s last quarter sales were recorded 4,209 M and last quarter income was 468,000 K.
